Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $18.46 million versus the consensus estimate of $23.56 million.

GUIDANCE:

Y-mAbs Therapeutics sees FY2024 revenue of $87-95 million, versus the consensus of $91.662 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.